A Unique Learning Platform
The ILCA School of Liver Cancer aims at delivering scientific education and helping progress ILCA’s mission to advance research in pathogenesis, prevention and treatment of liver cancer.
The ILCA School is a unique learning platform for practitioners and investigators to receive education in an intense, interactive and multidisciplinary format.
This annual educational event consists of 1,5 day courses focusing on a specific topic and is hosted in a Centre of Excellence worldwide which is selected based on application.
The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.
Participants learn about the principles and nuances of the diagnosis, management, and clinical investigation of liver cancer. The School’s intense, multidisciplinary and interactive format offers attendees state-of-the-art clinically relevant information regarding the disease.
- A residential, didactic and interactive format
- Dedicated time for one on one exchanges with a distinguished faculty and key opinion leaders
- A balanced seminar format involving multidisciplinary faculty
- Case-based examples for discussion emphasis
Fellows in gastroenterology and hepatology training programmes, junior faculty, basic/translational researchers and experienced clinicians with a desire to become more involved in liver cancer investigation and care.
ILCA School 2020
The next ILCA School of Liver Cancer will be virtual this December!
ILCA is very pleased to announce that the next edition of the ILCA School of Liver Cancer will be virtual this December 2020.
The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer-related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.
Sign today and join to get the deepest knowledge on:
- Understanding the pathogenesis of hepatocellular carcinoma and how to translate this knowledge in clinical practice
- Knowing the effect of antiviral treatment on the natural history of HCC
- Understanding the place of curative treatments (transplantation, resection and ablation) in management of early HCC
- Describing how radiology could help for the diagnosis and the assessment of the radiological response of HCC
- Defining the role of pathology in HCC management
- Discussing the evidence about SIRT and tyrosine kinase inhibitors in advanced HCC
|Friday, 11 December|
|Risk factors, screening and diagnosis of HCC: What is new?
(Chair: Valérie Paradis, Beaujon)
|08:25 – 08:30||Opening Remarks
Jean-Charles Nault (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris), Eric Vibert (Paul Brousse hospital, Villejuif, APHP): closing remarks
|08:30 – 08:45||The hepatocellular carcinoma session
Risk factors, screening and diagnosis of HCC: What is new?
Nathalie Ganne-Carrie (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris): Perspective on epidemiology and HCC screening in the era of NASH
|08:45 – 09:00||Understanding the physiopathology of NASH related HCC
Mathias Heikenwalder (Heidelberg, DKFZ)
|09:00 – 09:15||Update on the Imaging Diagnosis of HCC
Alain Luciani (Mondor Hospital, Créteil, APHP)
|09:15 – 09:30||The future of HCC pathology
Julien Calderaro (Mondor Hospital, Créteil, APHP)
|09:30 – 10:00||Blast session on hot topics: controversies in HCC screening and diagnosis (two 10 minute presentations + 10 minute discussion)
Pierre Nahon (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris): Impact of antiviral treatment on tumor occurrence and recurrence
François Durand (Beaujon Hospital, Clichy, APHP): Why and how to assess non-tumor liver in HCC patients?
|10:00 – 10:30||Virtual Coffee Break|
|Early HCC: can we go beyond guidelines?
(Chair: Michel Beaugrand, Bobigny)
|10:30 – 10:45||Sandra Rebouissou (Cordeliers research center, Paris): Preclinical models of HCC and prediction of therapeutic response|
|10:45 – 11:00||Eric Vibert (Paul Brousse hospital, Villejuif, APHP): Why and how to expend criteria for surgery?|
|11:00 – 11:15||Olivier Seror (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris): Current knowledge and innovation in percutaneous treatment of HCC|
|11:15 – 11:30||Blast session on hot topic: can we improve treatment of early HCC?
Olivier Scatton (Pitié-Salpétrière Hospital, Paris, APHP): The place of mini invasive surgery : short term advantages and bridge to liver transplantation
Christophe Duvoux (Mondor Hospital, Créteil, APHP): Can we expend criteria of liver transplantation beyond composite criteria ? (blast session: 2 X 10 mn presentation + 10 mn discussion)
|11:30 – 12:00||Break|
|Evidence and doubt about management of Intermediate HCC
Chair: Gregory Gores, Mayo Clinic
|12:00 – 12:15||Thierry De Baere (Institut Gustave Roussy, Villejuif): Current knowledge of endovascular treatment of HCC (except SIRT)|
|12:15 – 12:30||Maxime Ronot (Beaujon Hospital, Clichy, APHP): Assessment of radiological response: conventional and functional imaging of HCC|
|12:30 – 13:00||Blast session on hot topics: role of SIRT in 2020
Boris Guiu (CHU Montpellier): SIRT Pro
Tim Meyer (Royal Free Hospital, London): SIRT Against (blast session: 2 X 10 mn presentation followed by 10 mn discussion)
|13:00 – 14:00||Lunch|
|14:00 – 14:15||State of the art: Jessica Zucman-Rossi (Cordeliers research center, Paris) Genomic of hepatocellular carcinoma|
|Present and future of advanced HCC: immunotherapy
(Chair: Sandrine Faivre, Saint Louis Hospital)
|14:15 – 14:30||Amaia Lujambio (USA): liver immunology and HCC for the dummies|
|14:30 – 14:45||Thomas Decaens (CHU Grenoble): immunotherapy of HCC hope and hype|
|14:45 – 15:15||Blast session on hot topics: new questions rise with immunotherapy
Stéphane Champiat (Institut Gustave Roussy, Villejuif): Can we identify predictor of response to immunotherapy? The immuno-oncologist point of view
Mohamed Bouattour (Beaujon Hospital, Clichy, APHP): management of adverse events of immunotherapy
|Saturday, 12 December|
|Present and future of advanced HCC: targeted therapy
(Chair: Tim Meyer, Royal Free Hospital)
|15:30 – 15:45||Augusto Villanueva (Mount Sinai Hospital, New-York): Non-invasive biomarkers in HCC|
|15:45 – 16:00||Peter Galle (University Medical Center, Mainz): current and future role of targeted therapy in the management of advanced HCC|
|16:00 – 16:30||Blast session on hot topics: improving results of targeted therapy
Olivier Rosmorduc (Paul Brousse hospital, Villejuif, APHP): Potential role of combination therapy in HCC
Sandrine Faivre (Saint Louis Hospital, Paris, APHP): Reason of failure and success of phase 3 randomized controlled trial
|16:30 – 16:45||State of the Art: Pr Jordi Bruix Classification and treatment of HCC: a historical perspective|
|Clinical case: round of discussion|
|09:00 – 09:30||Early HCC
A multidisciplinary approach of a case (Panel: Daniel Cherqui, Valérie Paradis, Olivier Seror, Jordi Bruix)
Presentation of case report Manon Allaire (Pitié-Salpétrière, Paris, APHP): A small HCC with aggressive features
|09:30 – 10:00||A multidisciplinary approach of a case (Panel: Eric Vibert, Thierry De Baere, Sandrine Faivre, Olivier Rosmorduc)
Presentation of case report Marie Lequoy (Saint Antoine hospital, Paris, APHP): cholangiocarcinoma
|10:00 – 10:30||A multidisciplinary approach of a case (Panel: René Adam, Valérie Vilgrain, Christophe Duvoux, Jean Charles Nault)
Presentation of case report Giuliana Amaddeo (Mondor Hospital, Créteil, APHP): An intermediate HCC
|10:30 – 11:00||Break|
|11:00 – 11:15||Lars Zender (University of Tubingen) Pathogenesis of cholangiocarcinoma and cell of origin|
|11:15 – 11:30||Valérie Paradis (Beaujon Hospital, Clichy, APHP): primary liver cancers and mixed tumors: a continuum? the molecular biologist/pathologist point of view|
|11:30 – 11:45||Julien Edeline (Centre Eugène Marquis, Rennes) Systemic treatment of cholangiocarcinoma: to a personalized medicine|
|11:45 – 12:00||
Blast session on hot topics: what is the best option for curative treatment of intrahepatic and extrahepatic cholangiocarcinoma?
Olivier Soubrane (Beaujon Hospital, Clichy, APHP): Resection
Emmanuel Boleslaswki (Hôpital Huriez, CHU Lille): Transplantation
Registrations for the ILCA School of Liver Cancer 2020 are now open.
The ILCA School of Liver Cancer 2020 will take place virtually.
The ILCA School of Liver Cancer is supported by an unrestricted educational grant from Bristol-Myers Squibb